Swiss National Bank increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,200 shares of the company’s stock after acquiring an additional 7,900 shares during the period. Swiss National Bank owned approximately 0.16% of Privia Health Group worth $4,274,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the stock. Arizona State Retirement System raised its stake in shares of Privia Health Group by 6.4% in the fourth quarter. Arizona State Retirement System now owns 21,989 shares of the company’s stock valued at $499,000 after acquiring an additional 1,327 shares in the last quarter. Bleakley Financial Group LLC acquired a new stake in Privia Health Group in the fourth quarter valued at $348,000. Emerald Mutual Fund Advisers Trust raised its stake in Privia Health Group by 117.3% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 652,780 shares of the company’s stock valued at $14,825,000 after buying an additional 352,405 shares in the last quarter. Emerald Advisers LLC raised its stake in Privia Health Group by 87.3% in the fourth quarter. Emerald Advisers LLC now owns 836,069 shares of the company’s stock valued at $18,987,000 after buying an additional 389,615 shares in the last quarter. Finally, Spire Wealth Management raised its stake in Privia Health Group by 2,300.0% in the fourth quarter. Spire Wealth Management now owns 12,000 shares of the company’s stock valued at $273,000 after buying an additional 11,500 shares in the last quarter. 66.83% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, COO Parth Mehrotra sold 1,102 shares of the business’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $28.00, for a total transaction of $30,856.00. Following the completion of the sale, the chief operating officer now directly owns 97,391 shares of the company’s stock, valued at approximately $2,726,948. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Parth Mehrotra sold 1,102 shares of the company’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $28.00, for a total transaction of $30,856.00. Following the completion of the sale, the chief operating officer now directly owns 97,391 shares of the company’s stock, valued at approximately $2,726,948. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Advisors L.L.C. Mbd sold 24,819,473 shares of the company’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $21.61, for a total transaction of $536,348,811.53. Following the sale, the insider now directly owns 110,337 shares of the company’s stock, valued at $2,384,382.57. The disclosure for this sale can be found here. Insiders sold 25,371,773 shares of company stock valued at $551,840,171 in the last ninety days. Company insiders own 57.60% of the company’s stock.
Privia Health Group Stock Performance
Shares of PRVA opened at $25.36 on Friday. The stock has a fifty day moving average of $26.97 and a two-hundred day moving average of $25.95. The company has a market capitalization of $2.93 billion, a PE ratio of 230.55, a price-to-earnings-growth ratio of 3.13 and a beta of 0.77. Privia Health Group, Inc. has a fifty-two week low of $20.64 and a fifty-two week high of $44.64.
Privia Health Group (NASDAQ:PRVA – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.17. Privia Health Group had a net margin of 1.14% and a return on equity of 3.20%. The company had revenue of $364.42 million during the quarter, compared to analysts’ expectations of $337.16 million. As a group, equities research analysts forecast that Privia Health Group, Inc. will post 0.23 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
PRVA has been the topic of several research reports. Credit Suisse Group reaffirmed an “outperform” rating and set a $41.00 price objective on shares of Privia Health Group in a report on Tuesday, March 7th. Stephens initiated coverage on Privia Health Group in a report on Tuesday, April 11th. They set an “overweight” rating and a $33.00 price objective on the stock. The Goldman Sachs Group started coverage on Privia Health Group in a report on Friday, February 3rd. They set a “buy” rating and a $32.00 price objective on the stock. Royal Bank of Canada started coverage on Privia Health Group in a report on Thursday, March 9th. They set an “outperform” rating and a $36.00 price target on the stock. Finally, SVB Securities raised their price target on Privia Health Group from $39.00 to $40.00 in a report on Friday, May 5th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $39.19.
Privia Health Group Profile
(Get Rating)
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Featured Stories
Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Privia Health Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Privia Health Group wasn’t on the list.
While Privia Health Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
